首页> 外文期刊>Medical Molecular Morphology >Re-evaluation of histological type by immunohistochemical and genetic study of transcription factors (TFE3 and TFEB) of VHL gene mutation-negative clear cell renal cell carcinoma and other special types of renal tumor
【24h】

Re-evaluation of histological type by immunohistochemical and genetic study of transcription factors (TFE3 and TFEB) of VHL gene mutation-negative clear cell renal cell carcinoma and other special types of renal tumor

机译:通过免疫组化和对VHL基因突变阴性的透明细胞肾细胞癌和其他特殊类型肾肿瘤的转录因子(TFE3和TFEB)的遗传学研究重新评估组织学类型

获取原文
获取原文并翻译 | 示例
       

摘要

Translocation-type renal carcinoma has been recently discovered, and it is possible that this tumor may have been previously diagnosed as other types of renal tumor. We have subjected 41 renal tumors, including VHL gene mutation-negative clear cell renal cell carcinoma (RCC), papillary RCC, and chromophobe RCC, to immunohistochemistry of transcription factor E3 (TFE3) and TFEB. All tumors were histologically evaluated by additional immunohistochemical study. As a result, 5 tumors showed a positive reaction for TFE3 with a range from 1+ to 2+ in intensity. No tumors were positive for TFEB. In 5 tumors immunohistochemically positive for TFE3, chimeric transcripts including ASPL-TFE3, PRCC-TFE3, CLTCTFE3, PSF-TFE3, or Nono-TFE3 were not detected. The diagnosis of 6 tumors was changed by reevaluation through retrospective histological and immunohistochemical study. In 4 of 6 tumors, the diagnosis of clear cell RCC was changed to chromophobe RCC. In 1 tumor, oncocytoma was detectable, and RCC with rhabdoid features and sarcomatoid changes was detected in 1 tumor. Finally, the cutoff value of TFE3 immunohistochemistry should be more than 2+ with a wide range. The translocation-type renal carcinoma seems to be quite rare.
机译:最近发现了易位型肾癌,并且该肿瘤可能先前已被诊断为其他类型的肾肿瘤。我们已经对41种肾脏肿瘤(包括VHL基因突变阴性的透明细胞肾细胞癌(RCC),乳头状RCC和发色团RCC)进行了转录因子E3(TFE3)和TFEB的免疫组织化学研究。通过额外的免疫组织化学研究对所有肿瘤进行组织学评估。结果,有5个肿瘤显示TFE3呈阳性反应,强度范围为1+至2+。 TFEB无肿瘤阳性。在TFE3免疫组织化学阳性的5个肿瘤中,未检测到包括ASPL-TFE3,PRCC-TFE3,CLTCTFE3,PSF-TFE3或Nono-TFE3的嵌合转录物。通过回顾性组织学和免疫组化研究,通过重新评估改变了6种肿瘤的诊断。在6个肿瘤中的4个中,将透明细胞RCC的诊断改为发色RCC。在1个肿瘤中,可检测到肿瘤细胞瘤,在1个肿瘤中检测到具有横纹肌样特征和肉瘤样变化的RCC。最后,TFE3免疫组织化学的临界值应大于2+,且具有较宽的范围。易位型肾癌似乎非常罕见。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号